|Videos|July 14, 2022
CMV Transmission
Allison August, MD, Kathleen Muldoon, PhD, Stanley Plotkin, MD, and Patricia Purcell, MD, MPH, explore key strategies and takeaways that healthcare providers can use to discuss transmission of CMV with their patients.
Advertisement
Advertisement
Related to this article
AJOG research shows a cytokine storm could be detectable in maternal blood before the clinical onset of AFE.
CDC data show gestational hypertension rose 73% from 2016 to 2024, affecting 1 in 10 US mothers giving birth.
Missed the updated IDSA histoplasmosis guideline? This easy-to-read FAQ covers what clinicians caring for pregnant patients need to know.
The FDA accepted an sNDA and granted priority review for elinzanetant to treat VMS in women receiving endocrine therapy to treat or prevent HR+ breast cancer.
In the debut episode of Missed & Dismissed, Calbeth C. Alaribe, DMSc, MPH, PA-C, CPCHE, talks with Charis Chambers, MD, about PCOS, the push to rename it PMOS, and why diagnostic delays so often begin in adolescence.
Anita Nelson, MD, discusses the FDA's approval extending etonogestrel implant use to 5 years and the new REMS certification clinicians must complete by February 23, 2027.
Placentas from older mothers held less NAD+, and in aged pregnant mice, nicotinamide riboside or the CD38 inhibitor 78c restored placental NAD+ and improved fetal growth.
Hugh Taylor, MD, outlines a stepwise approach to endometriosis therapy, from first-line oral contraceptives to oral GnRH antagonists for progestin-resistant patients.
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
FDA grants priority review to elinzanetant for VMS in women receiving endocrine therapy for breast cancer
2
Q&A: Anita Nelson, MD, on etonogestrel implant's 5-year approval and REMS certification
3
Missed & Dismissed: The diagnostic gap starts in childhood
4
FAQ: How should clinicians manage histoplasmosis during pregnancy?
5